Key Developments

On February 07, 2024, Bristol Myers Squibb, a multinational pharmaceutical company, announced two regulatory approvals for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC)
On January 25, 2024, LAVA Therapeutics N.V., a clinical-stage biotechnology company, announced that it had entered into a clinical trial collaboration and supply agreement with Merck, a multinational pharmaceutical company, to evaluate its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in combination with LAVA-1207, a Gammabody designed to target the prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing of PSMA-positive tumor cells, in patients with therapy refractory metastatic castration-resistant prostate cancer (mCRPC).
On January 12, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved Merck's anti-PD-1 medication, KEYTRUDA, in combination with chemoradiotherapy (CRT), for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.
On January 08, 2024, Medison Pharma, a global pharmaceutical company, announced that it had signed an exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a leading biotechnology company, to commercialize Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and other markets worldwide.